StockData
Reviva Pharmaceuticals Holdings, Inc. logo

Reviva Pharmaceuticals Holdings, Inc. (RVPH) company profile

RVPHOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 2/30
$0.45−0.02 (-4.36%)

Close on Oct 19, 2026Market cap $5.94MP/E –Yield –

About Reviva Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Reviva Pharmaceuticals Holdings, Inc. is a pharmaceutical company that focuses on the clinical development of therapeutic drug candidates. Its primary product candidate in development is brilaroxazine, a chemical compound under evaluation for the treatment of patients with schizophrenia. The company conducts clinical trials to assess the safety and efficacy of this candidate. Because Reviva is currently engaged in drug research and clinical trials, the text identifies no commercial operating segments, and its prospective users are individuals diagnosed with schizophrenia.

The company is incorporated in Delaware and maintains its principal executive offices in Cupertino, California. Reviva conducts its administrative and corporate affairs from this single facility in the United States. The provided text lists no additional offices, retail locations, or international operations. Its operational scope is centered on managing its clinical programs and research activities from its California headquarters.

Summary of the business section of Reviva Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Reviva Pharmaceuticals Holdings, Inc.
Headquarters
Cupertino, CA
Address
10080 N Wolfe Road, Suite Sw3-200 95014
Phone
(408) 501-8881
Employees
14, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Baker Tilly US, LLP, San Francisco, CA

Stock & identifiers

Ticker
RVPH
Former tickers
TZACU until Mar 22, 2021
Exchange
OTC
IPO date
Aug 22, 2018
Shares outstanding
13M, Aug 13, 2026
Public float
$21.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-19.5 reverse, Mar 30, 2026; 1-for-20 reverse, Mar 9, 2026
SEC CIK
1742927
CUSIP
76152G209
ISIN
US76152G2093
FIGI
BBG00LJZ8FW8
Share class FIGI
BBG00LJZ8FX7
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Laxminarayan BhatPresident and CEO, Director2,484,244
Narayan PrabhuChief Financial Officer100,000
Parag SaxenaDirector4,046,000
Leslie D. FuntleyderDirector–
Purav PatelDirector75,607
Richard A. MargolinDirector–

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusTotalvs. prior year
Laxminarayan Bhat
Chief Executive Officer and President(3)
$450.00K$157.50K$607.50K-78%
Narayan Prabhu
Chief Financial Officer(4)
$325.00K$79.95K$404.95K-68%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Aug 22, 2018
Securities offered
5,500,000
Exchange
Nasdaq
First trading day
Dec 15, 2020
First-day close
$8.08
Lock-up ends (est.)
Jun 13, 2021

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“We have fourteen full-time employees, and utilize consultants, a contract research organization (“CRO”) and third parties to perform our pre-clinical studies, clinical studies, manufacturing, regulatory, administrative, and financial functions.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?